PREDICTMEDIX AI powered products use facial, thermal, video and audio recognition technologies to determine
when individuals are impaired,
suffering from infectious disease or mental illness.
CANNABIS AND ALCOHOL IMPAIRMENT
Our technology is quick, non-invasive, contactless screening that requires very little training to administer. It can be deployed easily in any workplace and easy to use for law enforcement officials. PredictMedix is the first solution to identify impairment and no need for any biologics.
Based on WHO report, an asymptomatic laboratory-confirmed case is a person infected with COVID-19 who does not develop symptoms. Asymptomatic transmission refers to transmission of the virus from a person, who does not develop symptoms. There are few reports of laboratory-confirmed cases who are truly asymptomatic, and to date, there has been no documented asymptomatic transmission. This does not exclude the possibility that it may occur. Asymptomatic cases have been reported as part of contact tracing efforts in some countries.
Data from published epidemiology and virologic studies provide evidence that COVID-19 is primarily transmitted from symptomatic people to others who are in close contact through respiratory droplets, by direct contact with infected persons, or by contact with contaminated objects and surfaces. This is supported by detailed experiences shared by technical partners via WHO global expert networks, and reports and presentations by Ministries of Health. As such based on current data, symptomatic transmission is responsible for the spread of COVID-19. Therefore, the key is to identify the majority of symptomatic individuals to prevent transmission which is the purpose of our mass screening technology.
The accuracy in identification of underlying symptoms of COVID-19 has an association with the sensitivity of multispectral cameras that are used for screening purposes. Therefore, we have minimum specifications for what is needed to ensure a high resolution can be maintained which can in turn ensure a high rate of accuracy. Our technology is designed to mass screen and encompass major symptoms associated with COVID-19 to ensure that most of the people who are likely to have COVID-19 are identified and prevented from entering the premises.
At the moment, any outbreak associated with common cold or flu is by default to be associated with COVID-19. Therefore health agencies are recommending that anyone who is showing associated symptoms avoid stepping out altogether. The only definitive way of distinguishing between common cold/flu/COVID-19 is a diagnostic test. Although currently we cannot between the two, our AI algorithms are deep learning based and as there is more data analyzed by the algorithms they get smarter.
The system can have the results usually within a fraction of the second (0.1-0.4 seconds) but at times due to low internet connectivity, it may extend to 1-2 seconds.
Typically internet bandwidth of above 25 Mbps should be needed for a single scan station.
The artificial intelligence (“AI”) powered technology utilizes multispectral imaging with a focus on visual spectral imaging along with infrared thermography to identify cases which are suspected of COVID-19. The AI technology monitors and identifies potential presence of COVID-19 associated symptoms such as fatigue, headache, coughing, sneezing, blood flow, sweat gland activation, metabolism, fever along with other key determinant factors.
The units provided are self-sufficient and only requires internet connectivity. Multispectral cameras installed within the units communicate with the cloud servers for analysis.